The role of parathyroid hormone during pregnancy on the relationship between maternal vitamin D deficiency and fetal growth restriction: a prospective birth cohort study

• Published in: British journal of nutrition 2020-08, Vol.124 (4), p.432-439
• Main Authors: Meng, Deng-Hong, Zhang, Ying, Ma, Shuang-Shuang, Hu, Hong-Lin, Li, Jing-Jing, Yin, Wan-Jun, Tao, Rui-Xue, Zhu, Peng
• Format: Article
• Language: English
• Subjects: 25-Hydroxyvitamin D; Birth weight; Calciferol; Chronic illnesses; Cohort analysis; Family income; Fetuses; Gestational age; Health risk assessment; Hospitals; Laboratories; Lifestyles; Medical records; Neonates; Nutritional Endocrinology; Parathyroid; Parathyroid hormone; Pregnancy; Pregnancy complications; Regression analysis; Risk; Small for gestational age; Supplements; Vitamin D; Vitamin deficiency; Weight
• ISSN: 0007-1145; 1475-2662
• DOI: 10.1017/S0007114520001105

Previous studies have shown conflicting findings regarding the relationship between maternal vitamin D deficiency (VDD) and fetal growth restriction (FGR). We hypothesised that parathyroid hormone (PTH) may be an underlying factor relevant to this potential association. In a prospective birth cohort study, descriptive statistics were evaluated for the demographic characteristics of 3407 pregnancies in the second trimester from three antenatal clinics in Hefei, China. The association of the combined status of vitamin D and PTH with birth weight and the risk of small for gestational age (SGA) was assessed by a multivariate linear and binary logistic regression. We found that declined status of 25-hydroxyvitamin D is associated with lower birth weight (for moderate VDD: adjusted β = −49·4 g, 95 % CI −91·1, −7·8, P < 0·05; for severe VDD: adjusted β = −79·8 g, 95 % CI −127·2, −32·5, P < 0·01), as well as ascended levels of PTH (for elevated PTH: adjusted β = −44·5 g, 95 % CI −82·6, −6·4, P < 0·05). Compared with the non-VDD group with non-elevated PTH, pregnancies with severe VDD and elevated PTH had the lowest neonatal birth weight (adjusted β = −124·7 g, 95 % CI −194·6, −54·8, P < 0·001) and the highest risk of SGA (adjusted risk ratio (RR) = 3·36, 95 % CI 1·41, 8·03, P < 0·01). Notably, the highest risk of less Ca supplementation was founded in severe VDD group with elevated PTH (adjusted RR = 4·67, 95 % CI 2·78, 7·85, P < 0·001). In conclusion, elevated PTH induced by less Ca supplementation would further aggravate the risk of FGR in pregnancies with severe VDD through impaired maternal Ca metabolism homoeostasis.